Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Vifor Pharma AG (VX: VIFN)

 
VIFN Technical Analysis
5
As on 20th Jan 2022 VIFN STOCK Price closed @ 161.90 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 126.29 & Strong Buy for SHORT-TERM with Stoploss of 122.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

VIFNSTOCK Price

Open 161.95 Change Price %
High 161.95 1 Day -0.10 -0.06
Low 161.30 1 Week -1.40 -0.86
Close 161.90 1 Month 40.65 33.53
Volume 362797 1 Year 40.15 32.98
52 Week High 164.00 | 52 Week Low 101.35
 
VX Switzerland Most Active Stocks
CSGN 9.13 0.77%
CSGN 9.13 0.77%
UBSG 17.68 0.11%
UBSG 17.68 0.11%
NOVN 81.39 -0.09%
NOVN 81.39 -0.09%
ABBN 34.39 1.15%
ABBN 34.39 1.15%
ARYN 1.11 -1.77%
ARYN 1.11 -1.77%
 
VX Switzerland Top Gainers Stocks
LOGN 74.68 2.50%
LOGN 74.68 2.50%
LOGN 74.68 2.50%
DUFN 49.60 2.42%
DUFN 49.60 2.42%
KNIN 270.00 2.27%
KNIN 270.00 2.27%
CLN 20.34 1.50%
CLN 20.34 1.50%
CLN 20.34 1.50%
 
VX Switzerland Top Losers Stocks
SGSN 2763.00 -2.61%
SGSN 2763.00 -2.61%
ADEN 49.45 -1.85%
ADEN 49.45 -1.85%
ARYN 1.11 -1.77%
ARYN 1.11 -1.77%
SLHN 587.40 -1.18%
SLHN 587.40 -1.18%
SREN 97.08 -0.41%
SREN 97.08 -0.41%
 
 
VIFN
Daily Charts		 VIFN
Intraday Charts		 Whats New @
Bazaartrend		 VIFN
Free Analysis
 
VIFN Important Levels Intraday
RESISTANCE163.15
RESISTANCE162.75
RESISTANCE162.50
RESISTANCE162.25
SUPPORT161.55
SUPPORT161.30
SUPPORT161.05
SUPPORT160.65
 
VIFN Forecast November 2024
Share
4th UP Forecast233.78
3rd UP Forecast210.73
2nd UP Forecast196.48
1st UP Forecast182.23
1st DOWN Forecast141.57
2nd DOWN Forecast127.32
3rd DOWN Forecast113.07
4th DOWN Forecast90.02
 
VIFN Weekly Forecast
4th UP Forecast181.17
3rd UP Forecast174.99
2nd UP Forecast171.17
1st UP Forecast167.35
1st DOWN Forecast156.45
2nd DOWN Forecast152.63
3rd DOWN Forecast148.81
4th DOWN Forecast142.63
 
VIFN Forecast2024
4th UP Forecast285.94
3rd UP Forecast246.16
2nd UP Forecast221.57
1st UP Forecast196.98
1st DOWN Forecast126.82
2nd DOWN Forecast102.23
3rd DOWN Forecast77.64
4th DOWN Forecast37.86
 
 
VIFN Other Details
Segment EQ
Market Capital 0.00
Sector Other
Industry Other
Offical website >
 
VIFN Address
VIFN
 
VIFN Latest News
 
Your Comments and Response on Vifor Pharma AG
 
VIFN Business Profile
Vifor Pharma AG develops, manufactures, and distributes pharmaceutical products in Switzerland, Europe, the United States, and internationally. It offers iron products, including Ferinject, Venofer, Maltofer, and Velphoro; Veltassa, a sodium-free potassium binder for the treatment of hyperkalaemia in adult patients; and Mircera, an erythropoiesis-stimulating agent for the treatment of symptomatic anemia associated with chronic kidney diseases. The company also provides infectious diseases/over-the-counter products, such as Broncho-Vaxom, an extract of various bacterial species for the treatment and prevention of recurrent respiratory infections; Uro-Vaxom, an extract of the bacterium Escherichia coli for the treatment and prevention of recurrent urinary tract infections; Dicynone for the prevention and treatment of capillary haemorrhages; Doxium for the oral treatment of diabetic retinopathy; and Aero-OM, an anti-flatulent for the oral treatment. Its development/pre-clinical products include VIT-2763, an oral ferroportin inhibitor, which is Phase I clinical trial for the treatment patients suffering from iron overload; Rayaldee for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) and vitamin D deficiency; Biosimilar epoetin alfa the treatment of anemia associated with CKD, renal failure, and chemotherapy-induced anemia; Avacopan/CCX168, an orally administered inhibitor; CCX140, an orally administered inhibitor of the chemokine receptor; and Vadadustat, an oral investigational hypoxia-inducible factor stabiliser that is in Phase-III development for the treatment of anemia related to CKD. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1927 and is headquartered in St. Gallen, Switzerland. Address:
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service